Cogent Accounts Payable from 2010 to 2025
COGT Stock | USD 6.90 0.50 6.76% |
Accounts Payable | First Reported 2017-12-31 | Previous Quarter 15.1 M | Current Value 12 M | Quarterly Volatility 4.4 M |
Check Cogent Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cogent Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 4.8 M or Selling General Administrative of 45.4 M, as well as many indicators such as Price To Sales Ratio of 35.83, Dividend Yield of 0.0 or PTB Ratio of 3.48. Cogent financial statements analysis is a perfect complement when working with Cogent Biosciences Valuation or Volatility modules.
Cogent | Accounts Payable |
Latest Cogent Biosciences' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Cogent Biosciences over the last few years. An accounting item on the balance sheet that represents Cogent Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Cogent Biosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Cogent Biosciences' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cogent Biosciences' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable | 10 Years Trend |
|
Accounts Payable |
Timeline |
Cogent Accounts Payable Regression Statistics
Arithmetic Mean | 3,847,791 | |
Geometric Mean | 2,487,590 | |
Coefficient Of Variation | 107.34 | |
Mean Deviation | 3,216,561 | |
Median | 1,454,000 | |
Standard Deviation | 4,130,399 | |
Sample Variance | 17.1T | |
Range | 11.9M | |
R-Value | 0.78 | |
Mean Square Error | 7.1T | |
R-Squared | 0.61 | |
Significance | 0.0003 | |
Slope | 678,408 | |
Total Sum of Squares | 255.9T |
Cogent Accounts Payable History
About Cogent Biosciences Financial Statements
Cogent Biosciences shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Cogent Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Cogent Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Cogent Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last Reported | Projected for Next Year | ||
Accounts Payable | 12 M | 12.6 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.